Table 3.
Amino acid sequences of 17 NSCLC patients with an exon 20 insertion
| No. | Sex | Age (yr) | Smoking Hx | ECOG | Initial stage | Exon 20 mutation | EGFR TKI | Chemotherapy | Best response | PFS | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 58 | Never | 1 | IIIA | c.2319_2320 ins CAC (p.H773_V774insH) | N/A | Premetrexed+cisplatin | SD | 17.0 | 46.4 |
| 2 | M | 73 | Never | 2 | IA | c.2319_2320 ins CAC (p.H773_V774insH) | N/A | N/A | 44.8 | ||
| 3 | M | 75 | Never | 1 | IV | C.2316_2317 ins GGCAACCCC (p.P772_H773insGNP) | N/A | Premetrexed+cisplatin | SD | 2.7 | 3.8 |
| 4 | M | 63 | Never | 1 | IIIA | c.2319_2320 ins CCCCAC (p.H773_V774insH) | N/A | Paclitaxel+cisplatin | PD | 0.9 | 9.7 |
| 5 | M | 50 | Never | 1 | IB | c.2305_2313 ins GTGGGGGTC (p.V769_N771insVGV) | N/A | N/A | 22.5 | ||
| 6 | F | 55 | Never | 1 | IV | c.2310_2311 ins GGT (p.D770_N771insG) | N/A | Premetrexed+cisplatin | PD | 1.9 | 6.1 |
| 7 | F | 63 | Never | 2 | IV | c.2322_2323 ins CACGTG (p.V774_C775insHV) | N/A | Premetrexed+cisplatin | SD | 2.1 | 18.4 |
| 8 | F | 55 | Never | 1 | IA | c.2322_2323 ins CACGTG (p.V774_C775insHV) | N/A | Premetrexed+cisplatin | PR | 13.0 | 26.2 |
| 9 | F | 56 | Never | 1 | IIIA | c.2319_2320 ins AACCCCCAC (p.H773_V774insNPH) | N/A | Docetaxel+cisplatin | PR | 2.7 | 29.5 |
| 10 | M | 60 | Never | 2 | IB | c.2319_2320 ins CCCCAC (p.H773_V774insPH | N/A | Premetrexed+cisplatin | PR | 2.6 | 46.4 |
| 11 | M | 48 | Never | 2 | IV | c.2315_2316 ins GACAACCCC (p.P772_H773insTTP) | N/A | Premetrexed+cisplatin | PR | 2.4 | 12.4 |
| 12 | F | 62 | Never | 1 | IA | c.2321_2322 ins CCACGT (p.V774_C775insHV) | N/A | N/A | 44.1 | ||
| 13 | F | 52 | Never | 1 | IA | c.2319_2320insCAC (p.H773_V774insH) | N/A | N/A | 35.2 | ||
| 14 | M | 60 | Never | 1 | IIIA | c.2319_2320insCAC (p.H773_V774insH) | N/A | Etoposide+cisplatin | PD | 2.6 | 25.9 |
| 15 | M | 60 | Never | 1 | IIIA | c.2319_2320insCAC (p.H773_V774insH) | N/A | Etoposide+cisplatin | SD | 17.2 | 26.2 |
| 16 | F | 66 | Never | 1 | IIIA | c.2318_2319 ins TAACCCCAG (p.H773_V774insPH) | N/A | Premetrexed+cisplatin | SD | 2.8 | 62.4 |
| 17 | M | 65 | Never | 1 | IA | c.2319_2320insCAC (p.H773_V774insH) | N/A | Premetrexed+cisplatin | PR | 2.9 | 36.9 |
The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys775insHisVal (17.6%) and His773_Val774insProHis (11.7%).
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; ECOG, Eastern Cooperative Oncology Group; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; F, female; N/A, not available; M, male; SD, stable disease; PD, progressive disease; PR, partial response.